|
Workshop
[Free Online Workshop] Antibody-Drug Conjugates: Discovery to Development
Speakers:
Ed Ha (Angiex), Dian Su (Genentech), Chunze Li (Genentech), Tao Li (Seattle Genetics), Melissa Schutten (Genentech)
Organizers:
Thomas Pillow (Genentech)
Date:
2021-05-26
Time:
8:30-13:30 Pacific Time
Registration fee:
(USD):
Location:
Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2021-05-24
(it will close sooner if the seating cap is reached)
About the Topic
Antibody-drug conjugates harness both the potent activity of a small molecule and the selectivity of a monoclonal antibody. This class of molecules has exploded in interest and success in recent years with >80 molecules undergoing clinical evaluation and 5 new ADCs approved since mid-2019. The workshop will provide the most recent learnings and critical aspects of the discovery and development for this class of bioconjugates.
Agenda:
8:30 am – 8:40 am Welcome Remarks -Thomas Pillow (Genentech; PBSS)
8:40 am - 9:25 am Chemistry and Conjugation of ADCs - Ed Ha (Angiex)
9:25 am - 10:10 am Small Molecule DMPK for ADCs - Dian Su (Genentech)
10:10 am - 10:55 am Dose Optimization for ADCs - Chunze Li (Genentech)
10:55 am - 11:05 am Major Sponsor Presentation - Catalent
11:05 am - 11:15 am Break
11:15 am - 12:00 pm CMC Challenges and Opportunities in ADC Drug Development - Tao Li (Seattle Genetics)
12:00 pm - 12:45 pm ADC Safety - Melissa Schutten(Genentech)
12:45 pm - 1:30 pm Panel Discussion - All speakers (Moderator: Thomas Pillow)
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Lena Biosciences
Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Submit a Text Ad
|